Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort.
Kuo-Tung TangJean-François DufourPo-Hung ChenRuben HernaezSusan M HutflessPublished in: BMJ open gastroenterology (2020)
In the short term, we did not observe a beneficial effect of anti-TNF-α agent use for development of cirrhosis, NAFLD or NASH in patients with immune-related diseases.
Keyphrases